MetaCap

Mineralys Therapeutics Inc. (MLYS)

NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.66-0.50 (-3.53%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MLYS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.30
52-week range
13.57 – 44.13
Day range
13.57 – 14.79
Volume / Avg
1.35M / 1.55M
Beta
—

52-week range

$13.57$44.13

MLYS stock today

Shares of Mineralys Therapeutics (MLYS) finished lower on Nov 20 at $13.66, a drop of 3.53% or $0.50 per share, versus the S&P 500's 3.70% decline. Shares are 69.0% below their 52-week high of $44.13, set on Nov 26, 2025 and 0.7% above the 52-week low of $13.57, near the bottom of the past year's range. MLYS is down 62.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.4%.

Mineralys Therapeutics has posted a net loss over the last twelve months (EPS of -$4.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Mineralys Therapeutics

Company profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jon Congleton
Headquarters
Radnor, PA
Employees
76
IPO year
2023

Financial highlights

Full financials

Mineralys Therapeutics reported a net loss of $154.7 million, compared with a loss of $177.8 million a year earlier. Diluted earnings per share came in at -$2.29.

Mineralys Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-154.65M$-177.81M$-71.90M$-29.80M
EPS (diluted)$-2.29$-3.66$-1.99$-5.77

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$43.56+218.89%

  • Strong buy 0
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $19.00High $56.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.64 vs $-0.53
Surprise
-20.75%

MLYS news

All MLYS news

Mineralys Therapeutics peers

Health Care sector
MLYS peer companies
CompanyPrice% ChgMarket capCompare
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs MLYS
GHRSGH Research PLC17.53-5.55%$1.20Bvs MLYS
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs MLYS
GENBGenerate Biomedicines Inc.9.54-8.00%$1.23Bvs MLYS
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs MLYS
MNKDMannKind Corporation3.85-2.53%$1.24Bvs MLYS
OPKOPKO Health Inc.1.57-2.48%$1.17Bvs MLYS
LBRXLB Pharmaceuticals Inc38.85-2.97%$1.26Bvs MLYS

Indexes, lists and sector

Mineralys Therapeutics stock FAQ

What is Mineralys Therapeutics's stock price today?

MLYS last traded at $13.66 as of Nov 20, 4:00 PM EST, down 3.53% on the day. Prices are delayed at least 15 minutes.

Who is Mineralys Therapeutics's CEO?

Dr. Jon Congleton is the chief executive officer of Mineralys Therapeutics Inc., which has about 76 employees.

What is the MLYS 52-week high?

The 52-week high for MLYS is $44.13 and the 52-week low is $13.57. The stock is currently 69.0% below its high.

Compare MLYS